13.74
-0.22(-1.58%)
Currency In USD
| Previous Close | 13.96 |
| Open | 14.2 |
| Day High | 14.71 |
| Day Low | 13.65 |
| 52-Week High | 24.27 |
| 52-Week Low | 4.06 |
| Volume | 2.52M |
| Average Volume | 1.5M |
| Market Cap | 155.18M |
| PE | -2.47 |
| EPS | -5.57 |
| Moving Average 50 Days | 15.68 |
| Moving Average 200 Days | 15.29 |
| Change | -0.22 |
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 17, 2025 9:30 PM GMT
WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
GlobeNewswire Inc.
Oct 29, 2025 11:00 AM GMT
WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the C
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
GlobeNewswire Inc.
Oct 01, 2025 11:00 AM GMT
WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expans